Literature DB >> 21185077

Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?

I Cetin1, B Huppertz, G Burton, H Cuckle, R Gonen, O Lapaire, L Mandia, K Nicolaides, C Redman, P Soothill, K Spencer, B Thilaganathan, D Williams, H Meiri.   

Abstract

The Pregenesys Consensus Meeting held in Cambridge on 13 July 2009 was organized by the Pregenesys Consortium to review and critically discuss current knowledge regarding early markers of preeclampsia, to identify priorities and opportunities for future research, to consider issues that may need to be addressed in future recommendations and to highlight key issues in cost effectiveness and national policies concerning prediction and early screening for the risk of developing preeclampsia. This report summarizes the outcome of the Consensus Meeting and draws attention to issues for further investigation with specific regard to single versus multiple markers, early versus late risk identification, and the long-term effects on both maternal and perinatal health and the need to include these in any future cost-benefit assessment. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 21185077     DOI: 10.1016/j.placenta.2010.11.022

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  16 in total

Review 1.  First trimester serum markers to predict preeclampsia.

Authors:  Berthold Huppertz; Rie Kawaguchi
Journal:  Wien Med Wochenschr       Date:  2012-05

Review 2.  Innate immunity, decidual cells, and preeclampsia.

Authors:  Chang-Ching Yeh; Kuan-Chong Chao; S Joseph Huang
Journal:  Reprod Sci       Date:  2012-07-18       Impact factor: 3.060

Review 3.  Mechanisms and management of hypertension in pregnant women.

Authors:  Catherine M Brown; Vesna D Garovic
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

Review 4.  Treatment of preeclampsia: current approach and future perspectives.

Authors:  Ecaterina Berzan; Ross Doyle; Catherine M Brown
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

5.  Protocadherin-12 cleavage is a regulated process mediated by ADAM10 protein: evidence of shedding up-regulation in pre-eclampsia.

Authors:  Stéphanie Bouillot; Emmanuelle Tillet; Guillaume Carmona; Marie-Hélène Prandini; Anne-Sophie Gauchez; Pascale Hoffmann; Nadia Alfaidy; Francine Cand; Philippe Huber
Journal:  J Biol Chem       Date:  2011-03-14       Impact factor: 5.157

Review 6.  Drug treatment of hypertension in pregnancy.

Authors:  Catherine M Brown; Vesna D Garovic
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

7.  Decreased levels of folate receptor-β and reduced numbers of fetal macrophages (Hofbauer cells) in placentas from pregnancies with severe pre-eclampsia.

Authors:  Zhonghua Tang; Irina A Buhimschi; Catalin S Buhimschi; Serkalem Tadesse; Errol Norwitz; Tracy Niven-Fairchild; Se-Te J Huang; Seth Guller
Journal:  Am J Reprod Immunol       Date:  2013-03-11       Impact factor: 3.886

8.  LIMK1 regulates human trophoblast invasion/differentiation and is down-regulated in preeclampsia.

Authors:  Yan Zhou; Akitoshi Yuge; Anthony M Rajah; Gozde Unek; Paolo F Rinaudo; Emin Maltepe
Journal:  Am J Pathol       Date:  2014-10-13       Impact factor: 4.307

9.  HtrA3 as an early marker for preeclampsia: specific monoclonal antibodies and sensitive high-throughput assays for serum screening.

Authors:  Kemperly Dynon; Sophea Heng; Michelle Puryer; Ying Li; Kelly Walton; Yaeta Endo; Guiying Nie
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

Review 10.  Prevention of preeclampsia.

Authors:  Sammya Bezerra Maia E Holanda Moura; Laudelino Marques Lopes; Padma Murthi; Fabricio da Silva Costa
Journal:  J Pregnancy       Date:  2012-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.